Open an account

Dogwood Therapeutics

DWTX · NASDAQ

$1.15−$0.06 (−4.96%)TodayMarket closed ·
Prev close $1.21

About DWTX

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 8 full-time employees. The company went IPO on 2020-12-17. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

Employees
8
Headquarters
Alpharetta, Georgia
Listed
Dec 17, 2020
Sector
Health Care
Industry
Biotechnology
Website
dwtx.com

DWTX key statistics

Market cap
39.09M
Price-earnings ratio
0.43
Dividend yield
—
Average volume
76.80K
Volume
50.35K
Open price
$1.22
High today
$1.26
Low today
$1.14
52 Week high
$7.04
52 Week low
$1.18

Dogwood Therapeutics (DWTX) at a glance

Dogwood Therapeutics (DWTX) last traded at $1.15, with a market cap of 39.09M and a price-to-earnings ratio of 0.43.

Today the stock has traded between $1.14 and $1.26. The current price is 0.9% above the day's low and 8.9% below its high.

Volume so far is 50.35K shares, below the average of 76.80K shares a day.

Over the past year Dogwood Therapeutics has ranged from $1.18 to $7.04, and now sits -1% of the way up that range.

Dogwood Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.1428.

The average analyst price target is $13.77, 1097.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $13.77
Low
$12.12
Now
$1.15
High
$15.75

DWTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 46.2% on average.

  1. Q3 FY24: reported -$2.05 per share against an estimate of -$1.20
  2. Q4 FY24: reported -$5.87 per share against an estimate of -$1.44
  3. Q1 FY25: reported -$4.19 per share against an estimate of -$2.42
  4. Q2 FY25: reported -$1.99 per share against an estimate of -$1.94
  5. Q3 FY25: reported -$8.20 per share against an estimate of -$1.25
  6. Q4 FY25: reported -$0.07 per share against an estimate of -$1.18
  7. Q1 FY26: reported -$0.15 per share against an estimate of -$0.2618
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.1428

DWTX news

  • Market-Moving News for September 29th

  • Avi Kapoor

    Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

  • Avi Kapoor

    Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

  • Avi Kapoor

    Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket

Similar companies

Companies in the same industry as Dogwood Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.